Seed Round Common Shares
21% equity
€11M pre-money
€0K raised
€3M target raise
Brain diseases affect 33% of the population in EU and US. One billion people suffer some type of brain disease, such as Alzheimer’s, Parkinson’s, MS, or stroke. Nowadays, still, much of the brain is a “black box” and most diseases are incurable as we do not know the causes or mechanisms.
Pharmaceutical companies are developing nearly 450 new drugs for brain diseases every year, however 95% of these drugs fail after a lengthy process with an average cost of $2.6 Billion because of poor measurements to evaluate the drug's efficacy or disease progression in patients. Insurmountable barriers for the development of new treatments are (1) the subjective evaluation of the symptoms of the disease - based on measures of cognitive performance and observations and (2) the inadequate patient profiling for the clinical trials.
Mint Labs offers a cloud-based platform for the handling of all brain images and related data with its data management, advanced analysis, 3D visualization, and sharing ca...
Brain diseases affect 33% of the population in EU and US. One billion people suffer some type of brain disease, such as Alzheimer’s, Parkinson’s, MS, or stroke. Nowadays, still, much of the brain is a “black box” and most diseases are incurable as we do not know the causes or mechanisms.
Pharmaceutical companies are developing nearly 450 new drugs for brain diseases every year, however 95% of these drugs fail after a lengthy process with an average cost of $2.6 Billion because of poor measurements to evaluate the drug's efficacy or disease progression in patients. Insurmountable barriers for the development of new treatments are (1) the subjective evaluation of the symptoms of the disease - based on measures of cognitive performance and observations and (2) the inadequate patient profiling for the clinical trials.
Mint Labs offers a cloud-based platform for the handling of all brain images and related data with its data management, advanced analysis, 3D visualization, and sharing capabilities. We aim to accelerate the pharmaceutical R&D pipelines by providing a quantitative evaluation about where the damage is, how extensive it is, how it affects the brain and if there are any changes - all is to understand the brain and to characterize patients.
Researchers and doctors conducting research on neurological diseases using brain images make up target customers as individuals and teams. The second target group is composed of research centers and hospitals where rigorous research and clinical trials are performed. The third group is comprised of Clinical Research Organizations (CROs) and pharmaceutical companies who conduct clinical trials on new drugs and treatments for neurological disorders. We estimate that the total Neuro-pharmaceutical market accounts for $495 billion. Even by only addressing the neuroimaging market for Alzheimer’s, Parkinson’s and Multiple Sclerosis, our potential market is $55 billion.
Our mission is unlock the value of imaging data to accelerate the discovery and development of new therapies for brain diseases to help save millions of lives. Therefore, our key metric is the number of brain datasets acquired and we have collected more than 280.000 brain scans since 2015. In addition to this, we have more than 450 customers, including more than 50 leading hospitals in the world such as UCSF, Beth Israel, Children's Hospital LA, and Hospital Clinic, in the EU and US.
More information
+2

Investors

Admin
FICHe Follow the Future Internet CHallenge eHealth!
Admin
FICHe Follow the Future Internet CHallenge eHealth!
Admin
Lisbon Challenge Accelerator Program International accelerator for startups in growth & traction phase
Admin
Wayra Telefonica's global tech accelerator with 12 offices in Europe & Latam

Join the team

Recommendations

Pablo Villoslada Founder & Sceintific Advisor at Bionure

Paulo is a superb engineer who has evolved to be a very successful entrepreneur. This means in addition of applying his expertise to medical imaging, developing the skills to eb a CEO of e medical engineering company. He has been smart for creating an amazing team, securing funding in series A and positioning the company into the the market in the competitive health care sector. Investing in Paulo is a path for success. Pablo Villoslada